Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis

Gaidukova, I E; Ребров, А. П.; Nam, In-Soo; Kirsanova, N V

doi:10.17116/terarkh2014861242-47

Cited by 5 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19]. Many other studies proved this protective effect of NSAIDs against active sacroiliitis [20,21]. On the other hand, some studies reported no changes were observed, in objective signs of inflammation on MRI and CRP levels, after taking NSAIDs [22].…”

Section: Discussionmentioning

confidence: 95%

Active Sacroiliitis on MRI, Inflammation Biomarkers, and Clinical Disease Activity: What Relationship Does Link Between the Three, in Non-Radiographic Axial Spondyloarthritis?

et al. 2020

View full text Add to dashboard Cite

Introduction: Magnetic resonance imaging of sacroiliac joints (MRI SI) is the gold standard imaging tool for axial spondyloarthritis (ax SpA) diagnosis, when the pelvic radiograph is normal or non-conclusive. In fact, subchondral bone marrow edema (BME) is the primary MRI feature of early ax SpA. The associated factors with active sacroiliitis on MRI are still not properly elucidate. The main objective of this study is to identify the relationship between active sacroiliitis on MRI, biomarkers of inflammation and Disease Activity Scores.Materials and methods: Our work could be categorized as a cross sectional study that enrolls all patients with non-radiographic axial spondyloarthritis (nr axSpA), meeting each; the assessment of SpondyloArthritis international Society axSpA criteria (ASAS 2009), and who were admitted in our Rheumatology Department, in the university hospital Hassan II of Fez (Morocco), all along the period laying between January 2012 and March 2018. The relationship between MRI-SI, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), C reactive protein and erythrocyte sedimentation rate was investigated. Results: 105 patients were involved in the study. The average age was [44years ± 13.5]. The Sex ratio was about [1.4]. 29 % of patients were smokers. 76% of cases had active sacroiliitis on MRI, while only 28% had inactive sacroiliitis. The average CRP serum level was roughly [23.5 ± 36mg / l]. On the other side, the ESR blood level was almost [25.9±24mm/h]. 94.2% of patients used non-steroidal antiinflammatory drugs (NSAIDs). The average ASDAS value was about [2.3 ± 1]. Whereas the BASDAI one was [4.2± 1], and the BASFI one was about [4± 1.5]. Actually, No significant relationship was found between active sacroiliitis and inflammation’s biomarkers. Indeed, men had 5.6 times more active sacroiliitis, of which smokers had even 3 times more the risk to develop active sacroiliitis, while treatment with NSAIDs was proved to be a protective factor. Conclusion: Biomarkers of inflammation cannot be used as a marker of objective inflammation of sacroiliac joints on MRI; hence, the necessity of MRI screening, and more additional studies with larger number of patients, should be conducted, to identify this association even better.

show abstract

Section: Discussionmentioning

confidence: 95%

Active Sacroiliitis on MRI, Inflammation Biomarkers, and Clinical Disease Activity: What Relationship Does Link Between the Three, in Non-Radiographic Axial Spondyloarthritis?

et al. 2020

View full text Add to dashboard Cite

show abstract

Pharmacologic Nonbiologic Treatment of Axial Spondyloarthritis

Proft¹,

Poddubnyy²

2019

Axial Spondyloarthritis

View full text Add to dashboard Cite

Efficacy of etoricoxib for ankylosing spondylitis

Tang

Yu²,

2019

Medicine

View full text Add to dashboard Cite

Background: Previous clinical trials have reported that etoricoxib has been utilized to treat ankylosing spondylitis (AS) effectively. However, no study systematically investigated the efficacy and safety of etoricoxib for patients with AS. In this systematic review, we will assess the efficacy and safety of etoricoxib for AS. Methods: The following electronic databases will be searched from inception to the February 1, 2019: Cochrane Library, Embase, PubMed, Cumulative Index to Nursing and Allied Health Literature, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and Chinese Scientific Journal Database. This study will include randomized controlled trials that explore the efficacy and safety of etoricoxib for AS. The primary outcome is pain intensity, as measured by any pain scales, such as Numerical Rating Scale. The secondary outcomes consist of AS function, as measured by Bath Ankylosing Spondylitis Functional Index, or other tools; quality of life, as assessed by Ankylosing Spondylitis Quality of Life questionnaire or any other relevant instruments; as well as adverse events. Two authors will independently carry out the study selection, data extraction, and risk of bias assessment. Statistical analysis will be performed by using RevMan 5.3 software. Results: This systematic review will provide a detailed summary of present evidence related to the efficacy and safety of etoricoxib for patients with AS. Conclusion: The results of this study may provide management guidance for AS treated by etoricoxib. Dissemination and ethics: This systematic review dose not needs ethical approval, because it will not analyze individual patient data. The findings of this study are expected to publish through a peer-reviewed journal. Systematic review registration: CRD42019124768.

show abstract

Etoricoxib in the treatment of active sacroiliitis in patients with axial spondyloarthritis, including ankylosing spondylitis

Cited by 5 publications

References 28 publications

Active Sacroiliitis on MRI, Inflammation Biomarkers, and Clinical Disease Activity: What Relationship Does Link Between the Three, in Non-Radiographic Axial Spondyloarthritis?

Active Sacroiliitis on MRI, Inflammation Biomarkers, and Clinical Disease Activity: What Relationship Does Link Between the Three, in Non-Radiographic Axial Spondyloarthritis?

Pharmacologic Nonbiologic Treatment of Axial Spondyloarthritis

Efficacy of etoricoxib for ankylosing spondylitis

Contact Info

Product

Resources

About